News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Indevus Pharmaceuticals, Inc. (IDEV) Announces Licensing Agreement Between Grupo Ferrer And IVAX Corporation (IVX) Related To Citicoline


10/19/2005 5:11:55 PM

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced a licensing agreement between Grupo Ferrer and IVAX Corporation for citicoline, an oral neuroprotective therapy for the treatment of stroke. Under the terms of this agreement, IVAX will be responsible for fulfilling the requirements for FDA approval of citicoline for acute stroke and for commercializing citicoline in the United States. The financial terms were not disclosed. Under an agreement between Indevus and Grupo Ferrer signed earlier this year, Indevus will receive a portion of milestone payments made to Ferrer by a third party in connection with the development of citicoline, as well as royalties on net sales of the product. In exchange, Indevus granted Ferrer exclusive rights to its patents and know-how related to citicoline.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES